Single nucleotide polymorphism mutation related genes in bladder cancer for the treatment of patients: a study based on the TCGA database

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Janisch F, Shariat SF, Schernhammer E, et al. The interaction of gender and smoking on bladder cancer risks. Curr Opin Urol. 2019;29(3):249–255.
   PubMed Web of Science ®Google Scholar
• Sanli O, Dobruch J, Knowles MA, et al. Bladder cancer. Nat Rev Dis Primers. 2017;3:17022.
   PubMed Web of Science ®Google Scholar
• Qi N, Zhang J, Chen Y, et al. Microscopic hematuria predicts lower stage in patients with upper tract urothelial carcinoma. Cancer Manag Res. 2018;10:4929–4933.
   PubMed Web of Science ®Google Scholar
• Khochikar MV. Rationale for an early detection program for bladder cancer. Indian J Urol. 2011;27(2):218–225.
   PubMedGoogle Scholar
• Kamat AM, Hahn NM, Efstathiou JA, et al. Bladder cancer. Lancet. 2016;388(10061):2796–2810.
   PubMed Web of Science ®Google Scholar
• Berdik C. Unlocking bladder cancer. Nature. 2017;551(7679):S34–S35.
   PubMed Web of Science ®Google Scholar
• Matsuda K. PCR-based detection methods for single-nucleotide polymorphism or mutation: real-time PCR and its substantial contribution toward technological refinement. Adv Clin Chem. 2017;80:45–72.
   PubMed Web of Science ®Google Scholar
• Srinivasan S, Clements JA, Batra J. Single nucleotide polymorphisms in clinics: fantasy or reality for cancer? Crit Rev Clin Lab Sci. 2016;53(1):29–39.
   PubMed Web of Science ®Google Scholar
• Gao C, Zhuang J, Zhou C, et al. SNP mutation-related genes in breast cancer for monitoring and prognosis of patients: a study based on the TCGA database. Cancer Med. 2019;8(5):2303–2312.
   PubMed Web of Science ®Google Scholar
• Liu C, Fang J, Liu W. Superoxide dismutase coding of gene polymorphisms associated with susceptibility to Parkinson's disease. J Integr Neurosci. 2019;18(3):299–303.
   PubMed Web of Science ®Google Scholar
• Wang CC, Huang CY, Jhuang YL, et al. Biological significance of TERT promoter mutation in papillary urothelial neoplasm of low malignant potential. Histopathology. 2018;72(5):795–803.
   PubMed Web of Science ®Google Scholar
• Robertson AG, Kim J, Al-Ahmadie H, TCGA Research Network, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171(3):540–556.e25.
   PubMed Web of Science ®Google Scholar
• Andrew AS, Gui J, Sanderson AC, et al. Bladder cancer SNP panel predicts susceptibility and survival. Hum Genet. 2009;125(5–6):527–539.
   PubMed Web of Science ®Google Scholar
• Li-Sheng CS, Ching-Yuan FJ, Sipeky C, et al. Risk prediction of prostate cancer with single nucleotide polymorphisms and prostate specific antigen. J Urol. 2019;201(3):486–495.
   PubMed Web of Science ®Google Scholar
• Inamura K. Bladder cancer: new insights into its molecular pathology. Cancers (Basel). 2018;10(4):100.
   PubMed Web of Science ®Google Scholar
• Kamps R, Brandão RD, Bosch BJ, et al. Next-generation sequencing in oncology: genetic diagnosis, risk prediction and cancer classification. Int J Mol Sci. 2017;18(2):308.
   PubMed Web of Science ®Google Scholar
• Han S, Kim D, Kim Y, et al. CAS-viewer: web-based tool for splicing-guided integrative analysis of multi-omics cancer data. BMC Med Genomics. 2018;11(Suppl 2):25.
   PubMedGoogle Scholar
• Mayakonda A, Lin DC, Assenov Y, et al. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747–1756.
   PubMed Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y, et al. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–287.
   PubMed Web of Science ®Google Scholar
• Bandettini WP, Kellman P, Mancini C, et al. Multicontrast delayed enhancement (MCODE) improves detection of subendocardial myocardial infarction by late gadolinium enhancement cardiovascular magnetic resonance: a clinical validation study. J Cardiovasc Magn Reson. 2012;14(1):83.
   PubMed Web of Science ®Google Scholar
• McCulloch K, Litherland GJ, Rai TS. Cellular senescence in osteoarthritis pathology. Aging Cell. 2017;16(2):210–218.
   PubMed Web of Science ®Google Scholar
• Regulski MJ. Cellular senescence: what, why, and how. Wounds. 2017;29(6):168–174.
   PubMed Web of Science ®Google Scholar
• Li R, Narici MV, Erskine RM, et al. Costamere remodeling with muscle loading and unloading in healthy young men. J Anat. 2013;223(5):525–536.
   PubMed Web of Science ®Google Scholar
• Meng T, Liu L, Hao R, et al. Transgelin-2: a potential oncogenic factor. Tumour Biol. 2017;39(6):1010428317702650.
   Google Scholar
• Nickerson ML, Witte N, Im KM, et al. Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response. Oncogene. 2017;36(1):35–46.
   PubMed Web of Science ®Google Scholar
• Felsenstein KM, Theodorescu D. Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy. Nat Rev Urol. 2018;15(2):92–111.
   PubMed Web of Science ®Google Scholar
• Zhu G, Pei L, Li Y, et al. EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients. Aging (Albany NY). 2020;12(3):2132–2141.
   PubMedGoogle Scholar
• Heide T, Maurer A, Eipel M, et al. Multiregion human bladder cancer sequencing reveals tumour evolution, bladder cancer phenotypes and implications for targeted therapy. J Pathol. 2019;248(2):230–242.
   PubMed Web of Science ®Google Scholar
• Chen S, Zhang N, Shao J, et al. A novel gene signature combination improves the prediction of overall survival in urinary bladder cancer. J Cancer. 2019;10(23):5744–5753.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang Y. Bladder cancer and genetic mutations. Cell Biochem Biophys. 2015;73(1):65–69.
   PubMed Web of Science ®Google Scholar
• Luo Y, Zeng G, Wu S. Identification of microenvironment-related prognostic genes in bladder cancer based on gene expression profile. Front Genet. 2019;10:1187.
   PubMed Web of Science ®Google Scholar
• Halstead AM, Kapadia CD, Bolzenius J, et al. Bladder-cancer-associated mutations in RXRA activate peroxisome proliferator-activated receptors to drive urothelial proliferation. Elife. 2017;6:e30862.
   PubMed Web of Science ®Google Scholar
• Indelicato E, Nachbauer W, Fauth C, et al. SYNE1-ataxia: novel genotypic and phenotypic findings. Parkinsonism Relat Disord. 2019;62:210–214.
   PubMed Web of Science ®Google Scholar
• Choi M, Kipps T, Kurzrock R. ATM mutations in cancer: therapeutic implications. Mol Cancer Ther. 2016;15(8):1781–1791.
   PubMed Web of Science ®Google Scholar
• Chen M, Sun X, Wang Y, et al. FAT1 inhibits the proliferation and metastasis of cervical cancer cells by binding β-catenin. Int J Clin Exp Pathol. 2019;12(10):3807–3818.
   PubMed Web of Science ®Google Scholar
• Lin SC, Lin LH, Yu SY, et al. FAT1 somatic mutations in head and neck carcinoma are associated with tumor progression and survival. Carcinogenesis. 2018;39(11):1320–1330.
   PubMed Web of Science ®Google Scholar
• Hu L, Xiao Y, Xiong Z, et al. MACF1, versatility in tissue-specific function and in human disease. Semin Cell Dev Biol. 2017;69:3–8.
   PubMed Web of Science ®Google Scholar
• Ho DWH, Chan LK, Chiu YT, et al. TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication. Gut. 2017;66(8):1496–1506.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang X, Tang W, et al. miR-130a upregulates mTOR pathway by targeting TSC1 and is transactivated by NF-κB in high-grade serous ovarian carcinoma. Cell Death Differ. 2017;24(12):2089–2100.
   PubMed Web of Science ®Google Scholar
• Jiang K, Liu H, Xie D, et al. Differentially expressed genes ASPN, COL1A1, FN1, VCAN and MUC5AC are potential prognostic biomarkers for gastric cancer. Oncol Lett. 2019;17(3):3191–3202.
   PubMed Web of Science ®Google Scholar
• Maggio I, Chen X, Gonçalves MA. The emerging role of viral vectors as vehicles for DMD gene editing. Genome Med. 2016;8(1):59.
   PubMedGoogle Scholar
• Juratli TA, McCabe D, Nayyar N, et al. DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome. Acta Neuropathol. 2018;136(5):779–792.
   PubMed Web of Science ®Google Scholar
• Musa H, Murphy NP, Curran J, et al. Common human ANK2 variant confers in vivo arrhythmia phenotypes. Heart Rhythm. 2016;13(9):1932–1940.
   PubMed Web of Science ®Google Scholar
• Hashemi-Gorji F, Yassaee VR, Dashti P, et al. Novel LAMA2 gene mutations associated with merosin-deficient congenital muscular dystrophy. Iran Biomed J. 2018;22(6):408–414.
   PubMedGoogle Scholar
• Shehadeh LA, Yu K, Wang L, et al. SRRM2, a potential blood biomarker revealing high alternative splicing in Parkinson's disease. PLoS One. 2010;5(2):e9104.
   PubMed Web of Science ®Google Scholar
• Tomsic J, He H, Akagi K, et al. A germline mutation in SRRM2, a splicing factor gene, is implicated in papillary thyroid carcinoma predisposition. Sci Rep. 2015;5:10566.
   PubMed Web of Science ®Google Scholar
• Bachir BG, Souhami L, Mansure JJ, et al. Phase I clinical trial of everolimus combined with trimodality therapy in patients with muscle-invasive bladder cancer. Bladder Cancer. 2017;3(2):105–112.
   PubMed Web of Science ®Google Scholar
• Lim KR, Maruyama R, Yokota T. Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Devel Ther. 2017;11:533–545.
   PubMed Web of Science ®Google Scholar
• Guenther LC, Kunynetz R, Lynde CW, et al. Acitretin use in dermatology. J Cutan Med Surg. 2017;21(3_suppl):2S–12S.
   PubMedGoogle Scholar